Early nucleoside therapy halts disease progression and restores motor function in infants, suggesting potential long-term benefits.
Early nucleoside therapy halts disease progression and restores motor function in infantile-onset TK2 deficiency, the most severe form of the disease.
No takes yet. Share an insight, caveat, or question.
Akinci et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: